NXTC

NextCure Inc.

Price

$6.16

return (12m)

20.08%

p/e

-0.69

p/bv

2.42

DIVIDEND YIELD

0.00%

NXTC price

NextCure

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NXTC

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

18.23%

3 months

-0.65%

1 year

20.08%

2 years

-67.51%

5 years

-93.08%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals NXTC

Valuation

P/E

-0.69

Sector -4.26

Industry -4.26

P/BV

2.42

Sector 2.11

Industry 2.11

P/Revenue (PSR)

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

1.30

Sector 1.25

Industry 1.25

P/Net Current Assets

2.50

Sector -5.47

Industry -5.47

P/Working Capital

1.86

Sector -1.10

Industry -1.10

EPS

-8.55

Sector -1.94

Industry -1.94

BVPS

2.43

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

0.00%

Sector 38.90%

Industry 38.90%

EBITDA Margin

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

0.00%

Sector -36.74%

Industry -36.74%

Net Profit Margins

0.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-351.85%

Sector -61.50%

Industry -61.50%

ROA

-188.99%

Sector -63.85%

Industry -63.85%

ROIC

0.00%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

3.47

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

0.00

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.00

Sector -0.83

Industry -0.83

Equity/Assets

0.54

Sector 0.43

Industry 0.43

Liabilities/Assets

0.46

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-9.23%

Sector -

Industry -

Fundamentals NXTC

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NXTC NextCure Inc.	$6.16	17.67%	0.00%	-0.69	2.42	-351.85%	0.00%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NXTC Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT NextCure

NextCure Inc.

Average Investor10 user rating

4.0 (2 people)

United States

11 years

Founded: 2015

2019

Time since IPO - 7 years

87

Employees

NextCure Inc. (United States) is listed on the Nasdaq and has a market capitalization of $29.45 million, with shareholders equity totaling $12.15 million.

The company employs approximately 87 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, NextCure Inc. reported $- in revenue, generating net income of $-42.75 million.

Key financial metrics include a P/E ratio of -0.69, a price-to-book (P/B) ratio of 2.42, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NXTC.

Market cap

$29.45 million

Net worth

$12.15 million

$12,150,000.00

Assets

$22.62 million

$22,620,000.00

Total Shares Outstanding

5.00 million

5,000,000

Average Daily Trading Volume

$2.68 million

$2,684,734.84

Sector

Health Care

Industry

Biotechnology

NXTC

NXTC revenue and profits

Financial Results NXTC

DRAG THE FRAME TO SEE MORE DATA

NXTC cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of NextCure (NXTC) today?

A cotação de NextCure (NXTC) hoje está em US$ 6.16, com uma variação de 20.08% em relação ao último ano. A cotação de NextCure (NXTC) iniciou o ano negociando na casa dos US$ 14.19 e hoje está em US$ 6.16. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de NextCure (NXTC) e dados de ações do Ibovespa e mercados internacionais.

Quando NextCure (NXTC) paga dividendos?

NextCure (NXTC) não distribuiu dividendos no último ano.

Is NextCure (NXTC) a good investment?

Atualmente, NextCure (NXTC) está cotada a US$ 6.16, com um P/L de -0.69, representando um desvio de -378% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 20.08 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 20.08%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy NextCure (NXTC) stock?

Investir em ações de NextCure (NXTC) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of NextCure (NXTC) yield today?

A rentabilidade de NextCure (NXTC) foi de 18.23% no último mês, 20.08% no último ano e -93.08% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de NextCure (NXTC) hoje, o investimento total seria de US$ 616.00, com base na cotação atual de US$ 6.16.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 739.69
Em 5 anos: US$ 42.63
Em 10 anos: US$ 616.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NXTC

NextCure Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NXTC

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING NXTC WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT NextCure

NextCure Inc.

United States

11 years

2019

87

PROFIT X PRICE NXTC

Financial Results NXTC

NXTC cash flow

Asset, Revenue and Profit Growth - NXTC

NXTC balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions